Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells

Prostate

Volumn 70, Issue 1, 2010, Pages 90-99

  Vander Griend, Donald J ^a,b   D'Antonio, Jason ^a,b   Gurel, Bora ^b   Antony, Lizamma ^a   DeMarzo, Angelo M ^b   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Cancer initiating cell; Human prostate cancer; Oncogene

Indexed keywords

ANDROGEN RECEPTOR; GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; GROWTH STIMULATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INTRACELLULAR FLUID; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 72849129206     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21043     Document Type: Article

References (38)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2(5):389-396.
2. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88(7):2972-2982.
3. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67(5): 417-434. (Pubitemid 40424552)
4. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGFI, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006;290(5):E952-E960.
5. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor- 10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274(18):12827-12834. (Pubitemid 129518057)
6. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL, Yamanaka H. Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor- 10. Endocr J 1999;46(3):405-413. (Pubitemid 29333948)
7. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80(8): 1251-1258. (Pubitemid 30637065)
8. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006;66(17):8598-8607. (Pubitemid 44449174)
9. Vander Griend DJ, Karthaus WK, Dalrymple S, Meeker AK, De Marzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer initiating cells. Cancer Res 2008;68(23):9703-9711.
10. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006;66:1329-1338. (Pubitemid 44384309)
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951. (Pubitemid 41713363)
12. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67(10):4807-4815. (Pubitemid 46910189)
13. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67(14): 6796-6805.
14. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98(4):756-765.
15. Sharifi N, Hurt EM, Farrar WL. Androgen receptor expression in prostate cancer stem cells: Is there a conundrum? Cancer Chemother Pharmacol 2008;62(5):921-923.
16. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003;62(5 Suppl 1): 11-20. (Pubitemid 37371885)
17. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. Prostate 2002;51(2):98-107.
18. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61(13):5038-5044. (Pubitemid 32681532)
19. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54(4):249-257.
20. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65(20): 9269-9279.
21. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edge-house NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56(13):3042-3046. (Pubitemid 126497722)
22. Gao J, Isaacs JT. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 1998; 58(15):3299-3306. (Pubitemid 28371069)
23. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91(1):196-205.
24. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM. Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate 2004;61(3):215-227. (Pubitemid 39350443)
25. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci USA 2006;103(41): 15085-15090. (Pubitemid 44583168)
26. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999;5(3):569-576.
27. Wikstrom P, Ohlson N, Stattin P, Bergh A. Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 2007;67(12): 1277-1284. (Pubitemid 47435775)
28. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005;63(1):19-28. (Pubitemid 40365387)
29. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68(13):5469-5477.
30. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62(4):1008-1013. (Pubitemid 34160279)
31. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 2007; 35(8): 2767-2776. (Pubitemid 47073687)
32. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61(16):6276-6280.
33. Pfeiffer MJ, Schalken JA. Stem cell characteristics in prostate cancer cell lines. Eur Urol 2009 [Epub ahead of print].
34. Hedlund TE, Miller GJ.Aserum-free definedmediumcapable of supporting growth of four established human prostatic carcinoma cell lines. Prostate 1994;24(5):221-228.
35. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001;8(2):192-200. (Pubitemid 32201366)
36. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8(4):580-588.
37. D'Antonio J, Vander Griend D, Isaacs J. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer 2009;16:325-332.
38. Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007;6(6):647-651. (Pubitemid 46535673)